REFERENCES
- Sillos EM, Shenep JL, Burghen GA, et al. Lactic acidosis: A metabolic complication of hematologic malignancies: Case report and review of the literature. Cancer 2001;92:2237 – 2246.
- Block JB, Bronson WR, Bell WR. Metabolic abnormalities of lactic acidosis in Burkitt-type lymphoma with malignant effusions. Annals of Internal Medicine 1966;65:101 – 108.
- Di Comite G, Dagna L, Piatti PM, et al. Hypoglycaemia and lactic acidosis in a MALT non Hodgkin’s lymphoma. Leukemia & Lymphoma 2002;43:1341 – 1342.
- Osorio S, Bernis C, de La Camara R. Lactic acidosis in Non- Hodgkin’s lymphoma and response to chemotherapy. Haematologica 2002;87:5.
- Braunwald E, Fauci AS, Kasper DL, et al. Harrison’s principles of internal medicine. 15th ed. New York, NY: McGraw-Hill Professional; 2001. pp 723 – 724, 2138.
- Evans AS, Mueller NE. Epstein-Barr virus and malignant lymphomas. In: Evans AS, Kaslow RA, editors. Viral infections of humans: Epidemiology and control. 4th ed. New York, NY: Plenum; 1997. pp 895 – 933.
- Oelkers W. Adrenal insufficiency. New England Journal of Medicine 1996;335:1206 – 1212.
- Krugmann J, Tzankov A, Fiegl M, et al. Burkitt’s lymphoma of the stomach: A case report with molecular cytogeneticanalysis. Leukemia & Lymphoma 2004;5:1055 – 1059.
- Devita VT, Hellman S, Rosenberg SA. Cancer: Principles and practice of oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins Publishers; 2001. pp 2640 – 2642.
- Narins RG, Krishna GG, Yee J, et al. The metabolic acidosis. In: Narins RG, editor. Maxwell & Kleeman’s clinical disorders of fluid and electrolyte metabolism. 5th ed. New York, NY: McGraw-Hill, Inc; 1994. pp 769 – 825.
- Abrahamian H, et al. Recurrent hypoglycemia and lactate acidosis in non-Hodgkin’s lymphoma. Deutsche Medizinische Wochenschrift 1991;116:1428 – 1432.
- Kahn CR. The riddle of tumour hypoglycaemia revisited. Clinical Endocrinology and Metabolism 1980;9:335 – 360. [13] Zapf J. Role of insulin-like growth factor II and IGF binding proteins in extrapancreatic tumor hypoglycemia. Hormone Research 1994;42: 20 – 26.
- Baxter RC. The role of insulin-like growth factor and their binding proteins in tumor hypoglycemia. Hormone Research 1996;46:195 – 201.
- Daughaday WH, Trivedi B, Baxter RC. Serum ‘‘big insulinlike growth factor II’’ from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing. Proceedings of the National Academy of Sciences of the United States of America 1993;90:5823 – 5827.
- Daughaday WH, et al. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. New England Journal of Medicine 1988;319:1434 – 1440.
- Baxter RC, Daughaday WH. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. The Journal of Clinical Endocrinology & Metabolism 1991;73:696 – 702.
- Shapiro ET, Bell GI, Polonsky KS, et al. (1990) Tumor hypoglycemia: relationship to high molecular weight insulinlike growth factor-II. Journal of Clinical Investigation 1990; 85:1672 – 1679.
- Zapf J, Futo E, Peter M, et al. Can ‘‘big’’ insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? Journal of Clinical Investigation 1992;90:2574 – 2584.
- Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Advances in Cancer Research 1996;68:183 – 223.